Aspirin resistance: Disparities and clinical implications

作者：Airee Anita^*; Draper Heather M; Finks Shannon W

来源：Pharmacotherapy, 2008, 28(8): 999-1018.

DOI：10.1592/phco.28.8.999

• aspirin resistance
• treatment failure
• platelet function tests
• coronary artery disease
• diabetes
• heart failure
• female
• stroke
• percutaneous coronary intervention
• PCI
• coronary artery bypass graft
• CABG

Aspirin is one of the most widely prescribed drugs for the prevention of thrombosis in patients with vascular disease. Yet, aspirin is unable to prevent thrombosis in all patients. The term "aspirin resistance" has been used to broadly define the failure of aspirin to prevent a thrombotic event. Whether this is directly related to aspirin itself through biochemical aspirin resistance or treatment failure, or if it is because of aspirin's inability to overcome the thrombogenic aspects of the disease process itself, has not been elucidated. This can have dramatic clinical implications for a variety of vascular disease subsets and is cause for concern, considering the high prevalence of aspirin use for both primary and secondary prevention. Disparities exist in the rates of aspirin resistance among certain patient populations, such as women, patients with diabetes mellitus, and those with heart failure, and across clinical conditions, such as cardiovascular and cerebrovascular disease. Clinical trial data from studies observing resistance have revealed that regardless of study size, dose of aspirin, control for drug interactions and adherence, or assay used to measure platelet function, aspirin resistance is associated with an increased risk for adverse events. Although the evidence is mounting, there has yet to be a consensus on the appropriate clinical response to aspirin resistance.

• 出版日期2008-8